Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990451 | 0.90 | KMT2A (0.50) | KAT2BPKMALDH1A1MAPTKMT2A | |
| SCHEMBL12235840 | 0.81 | HPGD (0.62) | CASP3HPGDPKMALDH1A1MAPT | |
| SCHEMBL18670938 | 0.73 | KAT2B (0.47) | CASP3KAT2BHPGDPKMALDH1A1 | |
| SCHEMBL5165436 | 0.73 | KAT2B (0.49) | CASP3KAT2BHPGDPKMALDH1A1 | |
| SCHEMBL2992093 | 0.72 | CASP3 (0.45) | CASP3KAT2BHPGDPKMALDH1A1 | |
| SCHEMBL12601339 | 0.72 | MEN1 (0.39) | PKMALDH1A1KMT2AMEN1 | |
| SCHEMBL28908599 | 0.72 | KMT2A (0.70) | ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL2998834 | 0.72 | CASP3 (0.42) | CASP3KAT2BHPGDALDH1A1MAPT | |
| SCHEMBL11453214 | 0.71 | HPGD (0.55) | HPGDPKMALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL29256393 | 0.71 | KMT2A (0.56) | HPGDPKMALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466191-B2 | Pyrroline derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof | ZHANG HESHENG (CN) | 2013-06-18 | — | — | US | disclosed |
| US-20100179189-A1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | ZHANG HESHENG | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179189-A1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | TNF, IL1B, NOS1 | CASP3 19/4885KAT2B 3405/4885HPGD 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.